Dialectic Therapeutics (DT) is a pre-clinical biotechnology company dedicated to the development of unique, impactful anti-cancer drugs that effectively treat patients with few to no other options. The company's drugs selectively induce cancer cells to degrade B-cell lymphoma and stimulate the cells to commit suicide or become susceptible to